Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 574 across all filing types
Latest filing 2019-12-02 Investor Presentation
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx Solutions AS - considering private placement
Investor Presentation Classification · 99% confidence The document is explicitly titled as a "Presentation" and the disclaimer states it was produced "solely for use at the presentation to investors held in connection with the proposed private placement of shares by the Company." It contains extensive forward-looking statements, risk factors, and information about product candidates and financing needs, which are characteristic features of materials prepared for potential investors. This strongly aligns with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR/IR).
2019-12-02 English
SoftOx Solutions AS - considering private placement
Share Issue/Capital Change Classification · 99% confidence The document text is extremely short (272 characters) and explicitly states, 'Please find an updated corporate presentation attached.' This indicates the document itself is an announcement about the availability of another document (a corporate presentation), rather than the presentation itself or a formal regulatory filing like a 10-K or IR. A corporate presentation is closely related to an Investor Presentation (IP). However, based on the 'MENU VS MEAL' rule, since this is an announcement of a document being attached/published, it should be classified as a Report Publication Announcement (RPA) or potentially a Regulatory Filing (RNS) if RPA doesn't fit. Since an Investor Presentation (IP) is a specific document type, and this is an announcement *of* that presentation, RPA is the most appropriate classification for the announcement itself, as per Rule 2.
2019-12-02 English
SoftOx signs distribution agreement with VESO, one of Norway’s leading companies for Animal Health.
Regulatory Filings Classification · 100% confidence The document text describes a specific business event: SoftOx signing a distribution agreement with VESO for animal health products. This is a material, non-financial announcement concerning business operations, partnerships, and market expansion. It does not fit the definitions for financial reports (10-K, IR, ER), capital changes (CAP, SHA), management changes (MANG), or shareholder votes (AGM-R, DVA). Since it is a specific corporate action announcement that doesn't fit the highly specific categories like Director's Dealing (DIRS) or M&A (TAR), the most appropriate general category for significant, non-standard corporate news is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2019-11-21 English
SOFTOX’ FIRST CLINICAL STUDY REVEALS POSITIVE EFFECTS IN ACUTE WOUNDS
Regulatory Filings Classification · 90% confidence The document is a press release dated October 9, 2019, announcing the successful completion of a first-in-man clinical trial (SWIS-01) for a wound rinsing product (SWIS). It details positive safety and performance results (bacterial reduction) and calls this an 'important milestone' and 'proof of concept'. It explicitly states that a 'comprehensive and detailed publication on the results will be published in a peer-reviewed Medical Journal.' Since this document is an announcement about clinical trial results and future publication, rather than the full financial report (10-K), earnings release (ER), or the detailed audit/test results themselves (AR), it best fits the category for general regulatory or corporate announcements that are not covered by more specific codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant corporate/clinical update that isn't a standard financial filing or management disclosure, although 'LTR' (Legal Proceedings Report) is sometimes used for regulatory outcomes, this is a positive clinical trial announcement. Since it is a general corporate announcement of a significant development, RNS is the best fit among the provided codes, as it is not a specific financial report, management change, or dividend notice.
2019-10-09 English
SOFTOX’ FIRST CLINICAL STUDY REVEALS POSITIVE EFFECTS IN ACUTE WOUNDS
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of the first clinical trial (SWIS-01) for a product called SWIS, detailing positive safety and performance results in acute wounds. It mentions that a comprehensive and detailed publication on the results will be published in a peer-reviewed Medical Journal. Since this is an announcement of study results, and not the full financial report (10-K), interim report (IR), or the detailed presentation (IP), it fits best as a general regulatory announcement or news release. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-financial, non-management-change announcement that doesn't fit other specific categories like LTR or DIV. It is not an Earnings Release (ER) as it concerns clinical data, not financial performance.
2019-10-09 English
SoftOx Solutions AS - fratredelse av styremedlem
Board/Management Information Classification · 100% confidence The document text is very short (274 characters) and announces the resignation ('fratredelse') of a board member ('styremedlem'), Dag Vangsnes, from SoftOx Solutions AS due to a change in his work situation. This directly relates to a change in the company's board of directors or senior management. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category (MANG). It is not a full report, a financial filing, or a general regulatory announcement.
2019-10-07 Norwegian

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.